Back to search
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) trials you may qualify forThis study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have to be hormone-receptor posit…
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary…
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combinat…
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.